196 related articles for article (PubMed ID: 36948091)
41. ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions.
Beéry E; Rajnai Z; Abonyi T; Makai I; Bánsághi S; Erdő F; Sziráki I; Herédi-Szabó K; Kis E; Jani M; Márki-Zay J; Tóth GK; Krajcsi P
Drug Metab Pharmacokinet; 2012; 27(3):349-53. PubMed ID: 22790065
[TBL] [Abstract][Full Text] [Related]
42. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
44. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
45. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
46. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A
Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464
[TBL] [Abstract][Full Text] [Related]
47. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
[TBL] [Abstract][Full Text] [Related]
48. Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.
Wright JA; Haslam IS; Coleman T; Simmons NL
Eur J Pharmacol; 2011 Dec; 672(1-3):70-6. PubMed ID: 22004608
[TBL] [Abstract][Full Text] [Related]
49. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
50. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
[TBL] [Abstract][Full Text] [Related]
51. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
[TBL] [Abstract][Full Text] [Related]
52. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
Choi MK; Song IS
J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
[TBL] [Abstract][Full Text] [Related]
53. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Muenster U; Grieshop B; Ickenroth K; Gnoth MJ
Pharm Res; 2008 Oct; 25(10):2320-6. PubMed ID: 18523872
[TBL] [Abstract][Full Text] [Related]
54. Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.
Gartzke D; Delzer J; Laplanche L; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Sydor J; Fricker G
Pharm Res; 2015 Jun; 32(6):2060-71. PubMed ID: 25522789
[TBL] [Abstract][Full Text] [Related]
55. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.
Zhang S; Morris ME
Pharm Res; 2003 Aug; 20(8):1184-91. PubMed ID: 12948016
[TBL] [Abstract][Full Text] [Related]
56. Reversible inhibition of efflux transporters by hydrogel microdevices.
Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
[TBL] [Abstract][Full Text] [Related]
57. Intestinal absorption mechanism of rotundic acid: Involvement of P-gp and OATP2B1.
Shang H; Sun Y; Wang Z; Zhou Y; Yang H; Ci X; Cui T; Xia Y; Gu Y; Liao M; Li Q; Si D; Liu C
J Ethnopharmacol; 2022 May; 289():115006. PubMed ID: 35051604
[TBL] [Abstract][Full Text] [Related]
58. Effect of Oregon grape root extracts on P-glycoprotein mediated transport in
Fan Y; Zhou Z; Zhang L
J Pharm Pharm Sci; 2023; 26():11927. PubMed ID: 38304488
[No Abstract] [Full Text] [Related]
59. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Zrieki A; Farinotti R; Buyse M
Pharm Res; 2008 Sep; 25(9):1991-2001. PubMed ID: 18581209
[TBL] [Abstract][Full Text] [Related]
60. Effects of Acanthopanax senticosus HARMS extract on drug transport in human intestinal cell line Caco-2.
Takahashi T; Kaku T; Sato T; Watanabe K; Sato J
J Nat Med; 2010 Jan; 64(1):55-62. PubMed ID: 20091240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
